؉ cytotoxic T lymphocytes (CTL). We have previously shown that female ␤ 2 -microglobulin-deficient (␤ 2 m؊/؊) mice, which are also deficient in CD8 ؉ T cells, are susceptible to LCMVinduced immune-mediated meningitis, characterized by significant weight loss and mortality. This LCMV disease in ␤ 2 m؊/؊ mice is mediated by CD4 ؉ T lymphocytes. Our previous studies have also demonstrated that male ␤ 2 m؊/؊ mice are less susceptible than female ␤ 2 m؊/؊ mice to LCMV-induced, immune-mediated mortality and weight loss. In this report, we show that vaccination of male ␤ 2 m؊/؊ mice enhances immunopathology following intracranial infection with LCMV. We observed increased production of gamma interferon (IFN-␥), an increase in CD4
Successful vaccination of hosts against viral infections depends on elicitation of appropriate humoral and/or cell-mediated immune responses (3) . Induction of virus-specific CD8 ϩ cytotoxic T lymphocytes (CTL) can protect hosts, most likely through lysis of virally infected cells (14, 46) . Induction of CD4 ϩ T lymphocytes can mediate antiviral protection by elaboration of lymphokines and by providing help for B cells in making antiviral antibody (46) . An optimal vaccine should stimulate both the CD8 ϩ and CD4 ϩ elements of cell-mediated immunity. In general, most successful vaccines result in protective, sterilizing immunity for their hosts; in certain instances, however, vaccination can actually enhance disease (4, 12, 30) . For example, vaccination of mice and humans against respiratory syncytial virus can result in enhanced disease mediated by CD4 ϩ T cells (4) . The classic viral model of vaccination inducing protective immunity versus immunopathology is the mouse model of lymphocytic choriomeningitis virus (LCMV) infection. Intracranial (i.c.) LCMV infection of immunologically competent mice results in a fatal immunopathologic meningitis mediated by CD8 ϩ CTL. Vaccination of immunocompetent mice elicits a CD8 ϩ CTL response that can either protect from immunopathology or enhance immunopathology, depending on the immune response of the particular mouse strain and the viral titer in the brain (30, 39) . Due to differences in both major histocompatibility complex (MHC)-and non-MHC-linked genes, different strains of mice respond differently to LCMV. For instance, low-responder strains of immunocompetent mice are not susceptible to immune-mediated mortality unless their immune responses are boosted by vaccination (30) . In highresponder mouse strains, protection from immune-mediated mortality following vaccination is due to an early increase in CD8 ϩ CTL that clear LCMV from the brain prior to the development of widespread immunopathology. On the other hand, certain rapidly replicating strains of LCMV exhaust CD8 ϩ CTL responses, resulting in persistent infection and absence of immunopathological disease (26) . Thus, for LCMV infection of immunocompetent mice, disease is dependent on a balance of brain viral titer and the developing CD8 ϩ CTL response.
Mice that have a disruption of the gene for ␤ 2 -microglobulin (␤ 2 mϪ/Ϫ mice) are profoundly deficient in CD8 ϩ , class I MHC-restricted CTL (17, 45) . Compared to immunocompetent mice, ␤ 2 mϪ/Ϫ mice undergo a less severe meningitis with delayed mortality, and they develop a wasting disease after i.c. LCMV infection (6, 12, 20, 27, 32) . In contrast to immunocompetent mice, in which CD8 ϩ CTL mediate disease, ␤ 2 mϪ/Ϫ mice develop CD4 ϩ T cells which mediate both lethal meningitis and wasting disease (6, 20, 27, 32, 44) . ␤ 2 mϪ/Ϫ mice also develop a persistent infection when infected with LCMV (6, 12, 20) . When mice are challenged i.c. with LCMV, there is a marked sex difference in immunopathologic responses to LCMV in which male ␤ 2 mϪ/Ϫ mice are much less susceptible to immune-mediated mortality and wasting disease than are females (28) . Vaccination of female ␤ 2 mϪ/Ϫ mice protects them from immune-mediated mortality despite persistent LCMV infection (12) . At the time of immune-mediated mortality, vaccinated and control female ␤ 2 mϪ/Ϫ mice had equivalent brain viral titers, suggesting that immunopathology is more dependent on the immune response than on the level of virus in the brain (12) . In the present study, we determined whether vaccination could alter LCMV-induced immunopathology in low-responder, male ␤ 2 mϪ/Ϫ mice and whether such alteration correlates with brain viral titers or with CD4 ϩ T-cell responses. To accomplish this, we vaccinated male ␤ 2 mϪ/Ϫ mice, challenged them with LCMV, and assessed their immune responses both in vivo and in vitro.
MATERIALS AND METHODS
Mice. ␤ 2 mϪ/Ϫ mouse breeding stocks were a kind gift from B. Koller (University of North Carolina at Chapel Hill) (17) . ␤ 2 mϪ/Ϫ mice are a recombinant inbred strain (129/Ola ϫ C57BL/6) and were used at F 8 to F 9 . All mice were maintained and bred in specific-pathogen-free animal facilities at the University of Wisconsin-Madison. Male mice were used between 6 and 18 weeks of age. All experimental protocols were reviewed and approved by the University Institutional Animal Care Committee.
Viruses. The Armstrong-3 strain of LCMV, a kind gift from Rafi Ahmed (Emory University, Atlanta, Ga.), was grown in BHK-21 cells; the number of PFU was assayed on Vero cells (1) . Control vaccinia virus (VV-sc11) and a recombinant vaccinia virus construct containing the coding region of the LCMV glycoprotein (VV-GP) gene were kind gifts from Maria Salvato and J. Lindsay Whitton (University of Wisconsin-Madison and Scripps Research Institute, La Jolla, Calif., respectively) (42) . These viruses were grown in HeLa-T4 cells, and the number of PFU was assayed on Vero cell monolayers (22) .
Inoculation and monitoring of mice. Mice were vaccinated intraperitoneally (i.p.) with 2 ϫ 10 7 PFU of control or recombinant vaccinia virus 25 days before challenge. For challenge with LCMV, mice were anesthetized with Metofane (Pittmann-Moore, Mundelein, Ill.) and injected i.c. with the indicated dose of virus in a volume of 30 l in Dulbecco modified Eagle medium (DMEM)-10% fetal calf serum (FCS). Mice were monitored daily for mortality. Wasting disease was defined as the loss of Ն20% of body weight for Ն8 days. Mice were weighed, and percent change in body weight was calculated as [(weight at day after challenge Ϫ weight at day of LCMV challenge)/weight at day of LCMV challenge] ϫ 100.
Cerebrospinal fluid (CSF) was obtained through the cisterna magna as described by Fleming et al. (7) . Briefly, a 27-gauge needle attached to a micropipette was used to puncture the cisterna magna, and a slight suction was applied to draw the CSF into the micropipette.
Cytokine enzyme-linked immunosorbent assays (ELISAs). Spleen cells were incubated with medium alone (RPMI 1640 supplemented with 10% FCS, 2 mM L-glutamine, 10 mM HEPES, 50 M 2-mercaptoethanol, 100 U of penicillin G and 100 g of streptomycin sulfate per ml), with LCMV-infected CH.B2 cells (10, 27) (10 4 cells/well), or with medium containing 100 U of recombinant human interleukin-2 (rhIL-2; a generous gift from Paul Sondel, University of Wisconsin-Madison) per ml in round-bottom 96-well microtiter plates (catalog no. 3799; Costar, Cambridge, Mass.). For anti-CD3 stimulation, CSF cells were incubated in flat-bottom 96-well microtiter plates coated with 1 g of anti-CD3 monoclonal antibody (MAb) (catalog no. CL7202AP; Cederlane, Hornby, Ontario, Canada) per ml. Cells (2 ϫ 10 5 ) were incubated in a final volume of 200 l/well for 24 h at 37°C and 5% CO 2 , after which plates were centrifuged (500 rpm for 5 min) and supernatants were removed and stored at Ϫ70°C.
For anti-CD4 depletions, 10 7 spleen cells were incubated in an appropriate dilution of GK1.5 (anti-CD4 Mab [5] ) or rat immunoglobulin G (product I4131; Sigma BioSciences, St. Louis, Mo.) and incubated for 60 min at 4°C. Rabbit complement (Low-Tox-M; Cedarlane) was added at a 1:10 dilution for 60 min at 37°C. Cells were washed and reconstituted to the original volume prior to the gamma interferon (IFN-␥) stimulations. Cells (2 ϫ 10 5 ) were stimulated in vitro as described above in a final volume of 200 l. Flow cytometric analysis showed that cells were Ͼ90% depleted (data not shown).
IFN-␥ and tumor necrosis factor alpha (TNF-␣) from cell culture supernatants were analyzed by double-sandwich ELISA as previously described (40 20 with 0.5% bovine serum albumin and incubated overnight at room temperature in a humid chamber. Recombinant murine IFN-␥ (lot no. M3 RD48; Genentech, South San Francisco, Calif.) and TNF-␣ (catalog no. 410-MT; R&D Systems, Minneapolis, Minn.) were used as standards, which gave reliable sensitivity to 24 pg/ml in both ELISAs. Secondary antibody (either polyclonal rabbit anti-mouse IFN-␥ [lot no. 5273-96Rb8A; Genentech] or rabbit anti-mouse TNF-␣ [catalog no. IP-400; Genzyme, Cambridge, Mass.]) was added at 1:1,000 dilution and incubated for 2 h at 37°C. Tertiary antibody (affinity-purified goat anti-rabbit immunoglobulin G-horseradish peroxidase conjugate [catalog 074-1506; KPL, Gaithersburg, Md.]) was added at 1:1,000 dilution and incubated for 2 h at 37°C. ABTS substrate and peroxide solution (catalog no. 50-62-00; KPL) were added, and the plates were read at 410 nm on a Dynatech MR 5000 ELISA reader.
Purification and in vitro stimulation of CD4 ؉ T cells. A single-cell suspension of spleen cells was pooled, washed, and incubated with anti-CD4 MicroBeads (catalog no. 492-01; Miltenyi Biotec, Inc., Auburn, Calif.) for 15 min at 4°C. Cells were washed twice in ice-cold PBS containing 10% FCS and placed on a steel wool column (type A2; Miltenyi Biotec) which was in the field of a strong magnet. The cells were equilibrated on the column and washed several times with ice-cold PBS containing 10% FCS. Cells were eluted from the column by removing the column from the magnet and flushing it with 100% FCS. Cells were incubated for 1 h at 37°C, after which 10 6 column-purified cells were stained with anti-CD4-fluorescein isothiocyanate (FITC) antibody (catalog no. 09004; PharMingen) to assess purification efficiency. Flow cytometric analysis showed that purified cells were consistently Ͼ85% CD4 ϩ (data not shown).
Dilutions of purified CD4
ϩ T cells were cultured with irradiated (2,800 rads), syngeneic feeder cells (4 ϫ 10 5 /well) which had been previously pulsed with UV-inactivated LCMV at a multiplicity of infection of 10 (12). Cells were cultured in DMEM supplemented with 10% FCS, 2 mM L-glutamine, 50 M 2-mercaptoethanol, 100 U of penicillin G and 100 g of streptomycin sulfate per ml, 10 U/ml rhIL-2, and 10 mM 3-(4-morpholino)-propanesulfonic acid in roundbottom 96-well microtiter plates in a final volume of 200 l for 7 days at 37°C and 5% CO 2 .
IFN-␥ ELISPOT. After 7 days of culture in vitro, purified CD4 ϩ T cells from individual wells were split; half of the cells were incubated with 4 g of concanavalin A (product no. C5275; Sigma) per ml, and the other half were incubated with medium alone in nitrocellulose-backed 96-well plates (catalog no. MAHA S45 10; Millipore, Marlborough, Mass.) in a final volume of 200 l/well. Prior to the addition of cells, ELISPOT plates were coated with 5 g of anti-IFN-␥ MAb (catalog no. 18181D; PharMingen) per ml and blocked with medium containing 10% FCS. Cells were incubated at 37°C and 5% CO 2 for 24 h. After incubation, cells were removed by washing with PBS, and plates were incubated with 2 g of biotinylated anti-IFN-␥ MAb (catalog no. 18112D; PharMingen) per ml overnight at 4°C. Plates were washed and incubated with 1:3,000-diluted streptavidin-horseradish peroxidase (catalog no. 1 089 153; Boehringer Mannheim) for 2 h at 37°C, after which spots were developed with 3-amino 9-ethylcarbazole-dimethylformamide substrate in 0.1 M sodium acetate buffer (pH 5.0)-0.015% H 2 O 2 . Spots were counted on a dissecting microscope (model M75; Wild, Heerbrugg, Switzerland). Positive wells were those having Ն3ϫ standard deviation above the average number of spots from cells incubated with medium alone. CD4
ϩ IFN-␥-producing cell precursor frequencies were calculated by using a chi-square minimization method as described by Taswell (38) .
CTLp frequency analysis. After 7 days of culture in vitro, purified CD4 ϩ T cells from individual wells were split; half of the cells were cultured with LCMVinfected, 51 Cr-labeled CH.B2 cells, and the other half were cultured with uninfected, 51 Cr-labeled CH.B2 cells. Effectors and targets (5 ϫ 10 3 cells/well) were incubated for 5 h at 37°C and 5% CO 2 in a final volume of 0.2 ml. Supernatants were harvested by using a Skatron harvesting apparatus (Skatron Instruments, Sterling, Va.) and counted in a Packard-␥ counter (Packard, Sterling, Va.). Percent specific lysis was calculated as (cpm targets ϩ effectors) Ϫ (spontaneous release)/(maximum release) Ϫ (spontaneous release) ϫ 100. Wells were counted as positive if the percent specific lysis on infected target cells was Ն15% higher than the lysis for uninfected targets. CTL precursor (CTLp) frequencies were calculated by using the chi-square minimization method of Taswell (38) .
Flow cytometry. Samples of 10 6 spleen or 10 5 CSF cells in 100 l were incubated with rat anti-mouse CD32 MAb (clone 2.4G2; PharMingen). Samples were washed and incubated with FITC-conjugated anti-mouse CD4 or CD8 MAb (clone RM4-5 or 53-6.7, respectively; PharMingen) and with phycoerythrin-conjugated anti-mouse-CD44 MAb (clone IM7; PharMingen). Samples were washed and fixed for 10 min in cold 4% paraformaldehyde. Samples were analyzed on a FACScan flow cytometer (Becton Dickinson, Mountain View, Calif.); data for 20,000 cells were acquired and analyzed by using Lysis II software (Becton Dickinson).
RESULTS
Effect of vaccination on weight loss and mortality in male ␤ 2 m؊/؊ mice. Compared to unvaccinated or control VV-sc11-vaccinated mice, VV-GP-vaccinated ␤ 2 mϪ/Ϫ mice had increased weight loss (Fig. 1A) and mortality (Fig. 1B) after LCMV challenge. Vaccination resulted in a significant increase in weight loss after LCMV challenge, as VV-GP-vaccinated mice lost between 25 and 35% of their body weight, compared to 8 to 15% in VV-sc11-vaccinated or unvaccinated mice. Weight loss in VV-GP-vaccinated mice began at day 6 and continued through day 24 after LCMV challenge; for VV-sc11-vaccinated mice, weight loss began at day 8 and continued through day 24 (Fig. 1A) . Vaccination of male, low-responder ␤ 2 mϪ/Ϫ mice thus enhanced both immunopathologic weight loss and mortality following i.c. LCMV challenge.
Effect of VV-GP vaccination on IFN-␥ production. LCMV disease observed in ␤ 2 mϪ/Ϫ mice is dependent on CD4 ϩ T cells (6, 20, 27, 32, 44) . Additionally, IFN-␥, a product of CD4 T-cell response, we compared levels of IFN-␥ production in vaccinated and control male ␤ 2 mϪ/Ϫ mice. Spleen cells from VV-GP-vaccinated mice released significantly more IFN-␥ when stimulated with either medium alone, IL-2, or LCMVinfected CH.B2 cells on day 4 compared to VV-sc11 controls ( Fig. 2A) . However, there were no significant differences observed at day 7 postchallenge (Fig. 2B) . Depletion of CD4 ϩ T cells with MAb GK1.5 in vitro before stimulation abrogated the production of IFN-␥, whereas treatment with an isotype control antibody did not, confirming that IFN-␥ was produced by CD4 ϩ T cells (data not shown). Vaccination of male ␤ 2 mϪ/Ϫ mice, therefore, elicited an early increase in CD4 ϩ T-cell production of IFN-␥.
Effect of VV-GP vaccination on CD4
؉ T-cell precursor frequencies. It was possible that the increased IFN-␥ production observed on day 4 was due either to an increase in the number of IFN-␥-producing cells or to an increased amount of IFN-␥ produced per cell. Therefore, we analyzed CD4 ϩ T-cell activation by flow cytometry and CD4
ϩ T-cell function by CTLp frequency and IFN-␥-producing cell precursor frequency. While we did not observe a significant difference in the percentage of CD4 ϩ CD44 hi cells (both groups were around 9% on day 4 and 23% on day 7), vaccinated male ␤ 2 mϪ/Ϫ mice had a significant increase in the absolute number of CD4 ϩ
CD44
hi cells in the spleen on day 4 post challenge (VV-sc11, 7.87 ϫ 10 6 cells/spleen; VV-GP, 1.52 ϫ 10 7 cells/spleen; P Ͻ 0.012). Likewise, analysis of CD4 ϩ T-cell function showed a significant increase in the frequency of IFN-␥-producing precursor cells on day 4 by limiting dilution ELISPOT analysis (Fig. 3A) . for control VV-sc11-vaccinated mice. We also observed a significant increase in CD4 ϩ CTLp frequency on day 4 by limiting dilution analysis (Fig. 3B) . The minimum estimate of the frequency of LCMV-specific CD4
ϩ CTLp was 1 in 21,479 for VV-GP-vaccinated mice and 1 in 90,390 for VV-sc11-vaccinated mice. In addition, spleen cells from VV-GP-vaccinated (but not LCMV-challenged mice) displayed LCMV-specific CTL activity against LCMV-infected CHB-2 target cells (data not shown). Thus, vaccination induced a quantitative difference in the number of CD4 ϩ T cells capable of IFN-␥ production and CTL activity, indicative of the increased immunopathology observed.
Effect of VV-GP vaccination on inflammation and IFN-␥ production in the CSF. Measurement of the CSF cellular exudate, which contains LCMV-specific cytotoxic effector cells, assesses inflammation of the meninges (6, 47) . Therefore, we compared inflammation between VV-GP-and VV-sc11-vaccinated mice by analyzing their CSF cells. VV-GP-vaccinated mice had significantly increased inflammation, as assessed by the number of mononuclear cells in the CSF on days 4 and 7 postchallenge (Fig. 4A) . The proportion of CD4 ϩ cells in the CSF of VV-GP-vaccinated mice on day 7 was higher than 50%, and over 93% of these were CD44 hi (data not shown). More importantly, VV-GP-vaccinated mice had an increase in the absolute number of CD4 ϩ T cells per l of CSF on both day 4 ϩ T-cell precursor frequency. Twenty-four wells at each dilution were split; half of each well was incubated with concanavalin A (4 g/ml), and the other half was incubated with media alone. (B) CD4
ϩ CTLp frequency. Twenty-four wells at each dilution were split; half of each well was incubated with LCMV-infected, 51 Cr-labeled targets, and the other half was incubated with uninfected, 51 Cr-labeled targets. Statistics were calculated by using the chi-square minimization method described by Taswell (38) . The precursor frequency range indicates the 95% confidence intervals for the values obtained. A significant difference was observed between the VV-sc11-and VV-GP-vaccinated groups for both CD4 ϩ IFN-␥-producing T-cell precursor frequency and CD4
ϩ CTLp frequency, as neither 95% confidence intervals overlap (P Ͻ 0.05).
FIG. 4. Increased inflammation and CD4
ϩ T-cell accumulation in the CSF of VV-GP-vaccinated male ␤ 2 mϪ/Ϫ mice. Groups (five mice/group) of male ␤ 2 mϪ/Ϫ were vaccinated i.p. with 2 ϫ 10 7 PFU of VV-sc11 (open bars) or VV-GP (closed bars) and were challenged i.c. 25 days later with 3 ϫ 10 4 PFU of LCMV. Mice were sacrificed at day 4 or day 7; CSF was removed from each mouse, and a sample was counted in a hemocytometer. CSF was then pooled and stained with FITC-conjugated anti-mouse CD4 and phycoerythrin-conjugated anti-mouse CD44 and analyzed by flow cytometry as described in 
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and day 7 postchallenge (Fig. 4B) . Finally, CSF cells from VV-GP-vaccinated mice stimulated with anti-CD3 MAb produced significantly more IFN-␥ than did cells from VV-sc11-vaccinated mice (Fig. 5) . TNF-␣ was not detected in the supernatants either from spleen cells or from cells isolated from the CSF (data not shown).
Viral titers in brain and spleen.
To test the hypothesis that differences in brain viral titer between VV-sc11-and VV-GPvaccinated mice could explain the difference in disease (12, 30), we measured brain and spleen viral titers on days 4 and 7 after LCMV challenge. As shown in Fig. 6 , there was no difference in the level of brain viral titer between these two groups at either day. Both groups also had high spleen viral titers (PFU/gram of tissue expressed as mean log 10 titer) on both days: VV-sc11, 5.06 on day 4 and 7.32 on day 7; VV-GP, 4.22 on day 4 and 7.62 on day 7. In addition, these titers remained at the level observed on day 7 in both groups until at least day 25 postinoculation (data not shown).
DISCUSSION
We have previously shown a marked gender difference in LCMV infection of ␤ 2 mϪ/Ϫ mice at the whole-animal level which is reflected at the level of CD4 ϩ T cells (28) . This finding suggests that female ␤ 2 mϪ/Ϫ mice possess enhanced CD4 ϩ T-cell activity in vivo (28) . This aspect of LCMV infection of ␤ 2 mϪ/Ϫ mice is particularly intriguing considering that several autoimmune diseases are more prevalent in women, and this susceptibility may be explained by enhanced CD4 ϩ T-cell activity (31) . Vaccination can protect female ␤ 2 mϪ/Ϫ mice from lethal immune-mediated meningitis despite persistent infection (12) . The mechanism of protection is not entirely clear. While vaccinated female ␤ 2 mϪ/Ϫ mice appear to have a slight early decrease in brain viral titer, there is no difference in brain viral titer between vaccinated (protected) and control (susceptible) mice at the time of immune-mediated mortality (12) . These results thus suggested that LCMV-induced immunopathology in female ␤ 2 mϪ/Ϫ mice may be more dependent on the magnitude and/or timing of the CD4 ϩ T-cell response than on the level of brain viral titer (12) .
We have previously shown that male ␤ 2 mϪ/Ϫ mice display an immunologically low-responder phenotype in response to LCMV infection (28) . In the present study, we determined that vaccination of male ␤ 2 mϪ/Ϫ mice leads to an increase in LCMV-induced immunopathology which correlates with an increase in CD4 ϩ T-cell responses but not with a change in brain viral titer. Vaccinated male ␤ 2 mϪ/Ϫ mice exhibited an earlier CD4 ϩ T-cell-dependent IFN-␥ response compared to controls. This early increase was due to an increase in the overall number of cells secreting IFN-␥. The CD4 ϩ IFN-␥-producing cell precursor frequencies that we found are lower than those previously described for LCMV infection of immunocompetent mice (8) . Likewise, the CD4 ϩ CTLp frequency that we observed is lower than the CD8 ϩ CTLp frequency in immunocompetent mice (25) , although it is similar to allospecific CD4
ϩ CTLp frequency in ␤ 2 mϪ/Ϫ mice (23). These lower precursor frequencies are not unexpected, as we and others have found lower and delayed CD4 ϩ T-cell responses in LCMV infection of ␤ 2 mϪ/Ϫ mice compared to CD8 ϩ T-cell responses in immunocompetent mice (6, 9, 20, 41) . Nonetheless, we have shown that vaccination induced a quantitative difference in the CD4 ϩ T-cell response which is likely responsible for increased disease in the whole animal.
The differences observed early in the spleen may simply be a reflection of the disease occurring in the central nervous system. The increase in disease following vaccination was also reflected in the CSF by a significant increase in inflammatory cells. Similar to the situation in the spleen, vaccinated mice had an increase in the absolute number of CD4 ϩ cells per microliter of CSF. The vast majority of these CD4 ϩ cells were of an activated phenotype (CD44 hi ), not unlike the case for immunocompetent mice, where the majority of the LCMV-specific CD8 ϩ effector cells express high levels of CD44 (35, 36) . Further, the higher number of CD4 ϩ CD44 hi cells in the CSF compared to the spleen suggests that the inflammation observed is due not to a nonspecific recruitment of inflammatory cells into the CSF but rather to activated CD4 ϩ T cells responding to LCMV antigens. Indeed, when CD4 ϩ T cells are depleted in vivo, the inflammation in the CSF is abrogated (6). The amount of virus in the brain does not appear to have any effect on the enhancement of disease, as there was no difference in brain viral titers between VV-GP-and VV-sc11-vaccinated mice.
LCMV-induced immunopathologic weight loss and mortality in ␤ 2 mϪ/Ϫ mice are clearly mediated by CD4 ϩ T cells (6, 20, 27, 32, 44) . We have shown here that vaccination increases immunopathologic weight loss, induces a quantitative increase in the CD4 ϩ T-cell response in the spleen and CSF, but does not affect brain viral titers. Taken together, these results suggest that enhancement of LCMV disease, at least in ␤ 2 mϪ/Ϫ mice, is more dependent on the magnitude and/or timing of the immune response rather than on the level of brain viral titer. These results are similar to what we found in female ␤ 2 mϪ/Ϫ mice (12) and are supported by recent observations in both human T-cell leukemia virus type 1 and human immunodeficiency virus infections, where virus load is not correlated with the magnitude of the CTL response (29) .
The results of this study, therefore, demonstrate an intriguing difference between LCMV infection of ␤ 2 mϪ/Ϫ and immunocompetent mice with respect to the enhancement of immunopathology. Whereas the CD8 ϩ CTL model is dependent on both a balance of brain viral titer and developing T-cell response, the CD4
ϩ T-cell model is more dependent on the magnitude and/or timing of the T-cell response than on the level of brain viral titer. This difference could be a reflection of differential activation requirements for the development of CD4 ϩ and CD8 ϩ T-cell-dependent immunopathology. In a similar system, two different strains of herpes simplex virus type 1 have been shown to elicit similar forms of immunopathology in the corneal infection model, one being CD4 ϩ T-cell mediated and the other being CD8ϩ T-cell mediated (11) . The authors of this study proposed that the observed difference resulted from the differential migration of antigen-presenting cells (APC) into the target organ. The difference between the CD4 ϩ T-cell and CD8ϩ T-cell LCMV models could similarly lie at the level of the APC. Indeed, the acute CD8 ϩ CTL response to LCMV seems not to require the same costimulatory molecules as CD4 ϩ T cells (18, 37) . Examination of differences in APC migration in the central nervous system between immunocompetent and ␤ 2 mϪ/Ϫ mice could thus provide insights for possible intervention in prevention of other immunopathologic diseases.
Although both wasting disease and mortality are mediated by CD4 ϩ T cells, as shown by in vivo depletion and adoptive transfer experiments (6, 20, 32) , we have shown that these two phenotypes are separable (12) . First, female ␤ 2 mϪ/Ϫ mice given high-dose (10 6 PFU) LCMV i.c. succumb to immunemediated mortality but do not develop wasting disease (12) . Second, female ␤ 2 mϪ/Ϫ mice vaccinated with recombinant vaccinia virus expressing LCMV genes are protected from lethal immune-mediated meningitis but not from wasting disease following LCMV challenge (12) . We therefore suspect that either distinct CD4 ϩ T-cell subpopulations or distinct effector mechanisms are responsible for these separate phenotypes. In support of the latter, ␤ 2 mϪ/Ϫ FasϪ/Ϫ mice (␤ 2 mϪ/Ϫ ϫ 1pr) do not succumb to lethal disease but do undergo wasting disease, suggesting a role for the Fas-FasL system in immunemediated mortality but not wasting disease (44) . The molecular mechanism of this type of wasting disease is still unclear. However, we have recently discovered through pair-feeding experiments that both the initial weight loss and the persistence of weight loss are due to a lack of food intake (11a). In addition, we have observed that significant weight loss occurs only after i.c. and not after i.p. LCMV infection, suggesting that the weight loss is centrally mediated (data not shown).
There are several cytokines that can act centrally to induce anorexia, including IFN-␥, IL-1, and TNF-␣ (33, 34) . Given that we observed substantial amounts of IFN-␥ produced from cells isolated from the CSF, it is likely that IFN-␥ and/or a downstream effector molecule such as IL-1 or TNF-␣ is responsible for this lack of food intake and ultimately for the weight loss observed. These hypotheses are currently under investigation.
Admittedly, one possible drawback of this model is that it excludes the influence of CD8 ϩ CTL. This can, however, also be viewed as a strength in that it allows the sole examination of the CD4 ϩ T-cell response mediating immunopathology in response to a noncytopathic virus that establishes a persistent infection. Indeed, we have shown that LCMV infection of ␤ 2 mϪ/Ϫ mice is a model whereby one can manipulate CD4 ϩ T-cell responses to a persistent viral infection through vaccination and have drastic effects on disease phenotype without influencing the persistent infection. In addition, it allows for direct comparisons between CD4 ϩ T-cell-and CD8 ϩ T-celldependent immunopathology to the same viral infection. The differences observed between these two models may reflect differential roles for CD4 ϩ and CD8 ϩ T cells in mediating immunopathologic disease. Therefore, this model may provide insights into situations whereby CD4 ϩ T cells mediate immunopathology independent of CD8 ϩ CTL responses such as cardiac allograft transplantation, coxsackie B virus infection, herpes simplex virus infection, and mouse and human hepatitis (2, 9, 11, 13, 24) . Also, recent studies point to the importance of immunopathological events during human immunodeficiency virus infection (16) . Our previous study showed that vaccination can be used to decrease immune-mediated pathology despite persisting infection (12) . Here we show that vaccination can also result in increased immunopathology in low responders. Further, this increased immunopathology is dependent not on the level of virus in the brain but rather on the magnitude of the immune response. Hence, this model may also have particular value in exploring the control of CD4 ϩ T-cell responses by using vaccination against persistent viral infections in order to prevent immunopathologic disease.
